Sarepta Therapeutics (SRPT) Competitors $62.92 +0.52 (+0.83%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. SMMT, TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, and ROIVShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Summit Therapeutics (NASDAQ:SMMT) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends, profitability and community ranking. Does the MarketBeat Community favor SMMT or SRPT? Sarepta Therapeutics received 1161 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 75.03% of users gave Sarepta Therapeutics an outperform vote while only 58.57% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes31158.57% Underperform Votes22041.43% Sarepta TherapeuticsOutperform Votes147275.03% Underperform Votes49024.97% Do analysts prefer SMMT or SRPT? Summit Therapeutics currently has a consensus target price of $37.50, indicating a potential upside of 55.47%. Sarepta Therapeutics has a consensus target price of $158.70, indicating a potential upside of 154.32%. Given Sarepta Therapeutics' higher probable upside, analysts clearly believe Sarepta Therapeutics is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83 Do insiders & institutionals believe in SMMT or SRPT? 4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, SMMT or SRPT? Sarepta Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K25,418.35-$614.93M-$0.31-77.81Sarepta Therapeutics$1.90B3.18-$535.98M$2.2827.37 Is SMMT or SRPT more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Summit Therapeutics' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Sarepta Therapeutics 7.43%11.00%3.35% Does the media refer more to SMMT or SRPT? In the previous week, Summit Therapeutics had 9 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 25 mentions for Summit Therapeutics and 16 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 1.00 beat Summit Therapeutics' score of 0.71 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, SMMT or SRPT? Summit Therapeutics has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. SummarySarepta Therapeutics beats Summit Therapeutics on 15 of the 19 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.05B$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio49.927.4422.4818.48Price / Sales3.18242.70395.93103.60Price / CashN/A65.8538.1834.62Price / Book6.796.516.774.25Net Income-$535.98M$143.21M$3.22B$248.23M7 Day Performance1.04%1.98%1.47%0.89%1 Month Performance0.79%6.89%3.99%3.53%1 Year Performance-52.33%-2.52%16.15%5.08% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.7356 of 5 stars$62.92+0.8%$158.70+152.2%-50.7%$6.10B$1.90B50.31840SMMTSummit Therapeutics2.6798 of 5 stars$25.18+2.3%$35.40+40.6%+513.7%$18.57B$700,000.00-89.93110Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries3.2702 of 5 stars$13.25-2.9%$23.43+76.8%+10.5%$15.02B$16.54B-9.1436,800Upcoming EarningsAnalyst UpgradeAnalyst RevisionPositive NewsGap UpITCIIntra-Cellular Therapies0.8793 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4448 of 5 stars$20.11+0.3%$39.17+94.8%-23.6%$13.31B$21.53B11.561,660Upcoming EarningsAnalyst RevisionPositive NewsRDYDr. Reddy's Laboratories1.8486 of 5 stars$13.66-0.1%$17.00+24.5%-5.3%$11.40B$311.31B21.7524,800Upcoming EarningsPositive NewsASNDAscendis Pharma A/S2.3116 of 5 stars$160.33-2.9%$204.67+27.7%+23.1%$9.78B$363.64M-22.58640Positive NewsMRNAModerna4.4322 of 5 stars$25.17+1.8%$58.70+133.2%-74.1%$9.73B$3.20B-2.713,900Earnings ReportNews CoverageGap DownVTRSViatris1.8326 of 5 stars$7.56flat$10.50+38.9%-27.2%$9.02B$14.74B-10.2237,000Upcoming EarningsQGENQiagen3.6936 of 5 stars$40.49-0.5%$47.83+18.1%+4.0%$9.00B$1.98B112.746,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.2052 of 5 stars$10.06-0.9%$17.50+74.0%+6.6%$7.18B$122.59M-67.06860Positive News Related Companies and Tools Related Companies Summit Therapeutics Competitors Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRPT Stock Free SRPT Stock Alerts